Role of osteopontin in the pathophysiology of cancer

Matrix Biology

Volumn 37, Issue , 2014, Pages 131-141

  Shevde, Lalita A ^a   Samant, Rajeev S ^a  

^a University of Alabama at Birmingham   (United States)

Author keywords

Cancer; Isoforms; Matricellular; Osteopontin; Signaling

Indexed keywords

OSTEOPONTIN; MULTIDRUG RESISTANCE PROTEIN; TUMOR MARKER;

ARTICLE; CLINICAL EVALUATION; HUMAN; MALIGNANT NEOPLASTIC DISEASE; MULTIPLE CANCER; NONHUMAN; PATHOPHYSIOLOGY; PROTEIN EXPRESSION; PROTEIN FUNCTION; PROTEIN STRUCTURE; REGULATORY MECHANISM; REPRESSOR GENE; CHEMISTRY; DISEASE COURSE; DRUG DELIVERY SYSTEM; METABOLISM; METASTASIS; NEOPLASM; PHYSIOLOGY; PROCEDURES; SIGNAL TRANSDUCTION; TUMOR INVASION;

DISEASE PROGRESSION; DRUG DELIVERY SYSTEMS; HUMANS; NEOPLASM INVASIVENESS; NEOPLASM METASTASIS; NEOPLASMS; OSTEOPONTIN; P-GLYCOPROTEINS; SIGNAL TRANSDUCTION; TUMOR MARKERS, BIOLOGICAL;

EID: 84908268897     PISSN: 0945053X     EISSN: 15691802     Source Type: Journal    
DOI: 10.1016/j.matbio.2014.03.001     Document Type: Review

References (166)

1. Ahmed M., Kundu G.C. Osteopontin selectively regulates p70S6K/mTOR phosphorylation leading to NF-kappaB dependent AP-1-mediated ICAM-1 expression in breast cancer cells. Mol. Cancer 2010, 9:101.
2. Allan A.L., George R., Vantyghem S.A., Lee M.W., Hodgson N.C., Engel C.J., Holliday R.L., Girvan D.P., Scott L.A., Postenka C.O., Al-Katib W., Stitt L.W., Uede T., Chambers A.F., Tuck A.B. Role of the integrin-binding protein osteopontin in lymphatic metastasis of breast cancer. Am. J. Pathol. 2006, 169:233-246.
3. Anborgh P.H., Mutrie J.C., Tuck A.B., Chambers A.F. Pre- and post-translational regulation of osteopontin in cancer. J. Cell Commun. Signal. 2011, 5:111-122.
4. Ashkar S., Weber G.F., Panoutsakopoulou V., Sanchirico M.E., Jansson M., Zawaideh S., Rittling S.R., Denhardt D.T., Glimcher M.J., Cantor H. Eta-1 (osteopontin): an early component of type-1 (cell-mediated) immunity. Science 2000, 287:860-864.
5. Atai N.A., Bansal M., Lo C., Bosman J., Tigchelaar W., Bosch K.S., Jonker A., De Witt Hamer P.C., Troost D., McCulloch C.A., Everts V., Van Noorden C.J., Sodek J. Osteopontin is up-regulated and associated with neutrophil and macrophage infiltration in glioblastoma. Immunology 2011, 132:39-48.
6. Bellahcene A., Castronovo V. Increased expression of osteonectin and osteopontin, two bone matrix proteins, in human breast cancer. Am. J. Pathol. 1995, 146:95-100.
7. Berge G., Pettersen S., Grotterod I., Bettum I.J., Boye K., Maelandsmo G.M. Osteopontin-an important downstream effector of S100A4-mediated invasion and metastasis. Int. J. Cancer 2011, 129:780-790.
8. Bhattacharya S.D., Garrison J., Guo H., Mi Z., Markovic J., Kim V.M., Kuo P.C. Micro-RNA-181a regulates osteopontin-dependent metastatic function in hepatocellular cancer cell lines. Surgery 2010, 148:291-297.
9. Boissy P., Andersen T.L., Abdallah B.M., Kassem M., Plesner T., Delaisse J.M. Resveratrol inhibits myeloma cell growth, prevents osteoclast formation, and promotes osteoblast differentiation. Cancer Res. 2005, 65:9943-9952.
10. Boudjadi S., Bernatchez G., Beaulieu J.F., Carrier J.C. Control of the human osteopontin promoter by ERRalpha in colorectal cancer. Am. J. Pathol. 2013, 183:266-276.
11. Boyerinas B., Zafrir M., Yesilkanal A.E., Price T.T., Hyjek E.M., Sipkins D.A. Adhesion to osteopontin in the bone marrow niche regulates lymphoblastic leukemia cell dormancy. Blood 2013, 121:4821-4831.
12. Bramwell V.H., Tuck A.B., Wilson S.M., Stitt L.W., Cherian A.K., Rorke S.C., Al-Katib W., Postenka C.O., Chambers A.F. Expression of osteopontin and HGF/met in adult soft tissue tumors. Cancer Biol. Ther. 2005, 4:1336-1341.
13. Bramwell V.H., Doig G.S., Tuck A.B., Wilson S.M., Tonkin K.S., Tomiak A., Perera F., Vandenberg T.A., Chambers A.F. Serial plasma osteopontin levels have prognostic value in metastatic breast cancer. Clin. Cancer Res. 2006, 12:3337-3343.
14. Cerami E., Gao J., Dogrusoz U., Gross B.E., Sumer S.O., Aksoy B.A., Jacobsen A., Byrne C.J., Heuer M.L., Larsson E., Antipin Y., Reva B., Goldberg A.P., Sander C., Schultz N. The cBio cancer genomics portal: an open platform for exploring multidimensional cancer genomics data. Cancer Discov. 2012, 2:401-404.
15. Chagan-Yasutan H., Tsukasaki K., Takahashi Y., Oguma S., Harigae H., Ishii N., Zhang J., Fukumoto M., Hattori T. Involvement of osteopontin and its signaling molecule CD44 in clinicopathological features of adult T cell leukemia. Leuk. Res. 2011, 35:1484-1490.
16. Chakraborty G., Jain S., Kale S., Raja R., Kumar S., Mishra R., Kundu G.C. Curcumin suppresses breast tumor angiogenesis by abrogating osteopontin-induced VEGF expression. Mol. Med. Rep. 2008, 1:641-646.
17. Chakraborty G., Jain S., Kundu G.C. Osteopontin promotes vascular endothelial growth factor-dependent breast tumor growth and angiogenesis via autocrine and paracrine mechanisms. Cancer Res. 2008, 68:152-161.
18. Chang P.L., Cao M., Hicks P. Osteopontin induction is required for tumor promoter-induced transformation of preneoplastic mouse cells. Carcinogenesis 2003, 24:1749-1758.
19. Chang P.L., Harkins L., Hsieh Y.H., Hicks P., Sappayatosok K., Yodsanga S., Swasdison S., Chambers A.F., Elmets C.A., Ho K.J. Osteopontin expression in normal skin and non-melanoma skin tumors. J. Histochem. Cytochem. 2008, 56:57-66.
20. Chang W.L., Yang H.B., Cheng H.C., Chuang C.H., Lu P.J., Sheu B.S. Increased gastric osteopontin expression by Helicobacter pylori Infection can correlate with more severe gastric inflammation and intestinal metaplasia. Helicobacter 2011, 16:217-224.
21. Chang S.H., Minai-Tehrani A., Shin J.Y., Park S., Kim J.E., Yu K.N., Hong S.H., Hong C.M., Lee K.H., Beck G.R., Cho M.H. Beclin1-induced autophagy abrogates radioresistance of lung cancer cells by suppressing osteopontin. J. Radiat. Res. 2012, 53:422-432.
22. Chen J., Wu Q., Lu Y., Xu T., Huang Y., Ribas J., Ni X., Hu G., Huang F., Zhou L., Lu D. SPP1 promoter polymorphisms and glioma risk in a Chinese Han population. J. Hum. Genet. 2010, 55:456-461.
23. Chen Y., Liu H., Wu W., Li Y., Li J. Osteopontin genetic variants are associated with overall survival in advanced non-small-cell lung cancer patients and bone metastasis. J. Exp. Clin. Cancer Res. 2013, 32:45.
24. Cheng H.C., Liu Y.P., Shan Y.S., Huang C.Y., Lin F.C., Lin L.C., Lee L., Tsai C.H., Hsiao M., Lu P.J. Loss of RUNX3 increases osteopontin expression and promotes cell migration in gastric cancer. Carcinogenesis 2013, 34:2452-2459.
25. Chuang C.Y., Chang H., Lin P., Sun S.J., Chen P.H., Lin Y.Y., Sheu G.T., Ko J.L., Hsu S.L., Chang J.T. Up-regulation of osteopontin expression by aryl hydrocarbon receptor via both ligand-dependent and ligand-independent pathways in lung cancer. Gene 2012, 492:262-269.
26. Collins A.L., Rock J., Malhotra L., Frankel W.L., Bloomston M. Osteopontin expression is associated with improved survival in patients with pancreatic adenocarcinoma. Ann. Surg. Oncol. 2012, 19:2673-2678.
27. Cook A.C., Tuck A.B., McCarthy S., Turner J.G., Irby R.B., Bloom G.C., Yeatman T.J., Chambers A.F. Osteopontin induces multiple changes in gene expression that reflect the six "hallmarks of cancer" in a model of breast cancer progression. Mol. Carcinog. 2005, 43:225-236.
28. Cook A.C., Chambers A.F., Turley E.A., Tuck A.B. Osteopontin induction of hyaluronan synthase 2 expression promotes breast cancer malignancy. J. Biol. Chem. 2006, 281:24381-24389.
29. Coppola D., Szabo M., Boulware D., Muraca P., Alsarraj M., Chambers A.F., Yeatman T.J. Correlation of osteopontin protein expression and pathological stage across a wide variety of tumor histologies. Clin. Cancer Res. 2004, 10:184-190.
30. Craig A.M., Smith J.H., Denhardt D.T. Osteopontin, a transformation-associated cell adhesion phosphoprotein, is induced by 12-O-tetradecanoylphorbol 13-acetate in mouse epidermis. J. Biol. Chem. 1989, 264:9682-9689.
31. Creaney J., Yeoman D., Musk A.W., de Klerk N., Skates S.J., Robinson B.W. Plasma versus serum levels of osteopontin and mesothelin in patients with malignant mesothelioma-which is best?. Lung Cancer 2011, 74:55-60.
32. Cristaudo A., Bonotti A., Simonini S., Vivaldi A., Guglielmi G., Ambrosino N., Chella A., Lucchi M., Mussi A., Foddis R. Combined serum mesothelin and plasma osteopontin measurements in malignant pleural mesothelioma. J. Thorac. Oncol. 2011, 6:1587-1593.
33. Das R., Mahabeleshwar G.H., Kundu G.C. Osteopontin induces AP-1-mediated secretion of urokinase-type plasminogen activator through c-Src-dependent epidermal growth factor receptor transactivation in breast cancer cells. J. Biol. Chem. 2004, 279:11051-11064.
34. Das S., Harris L.G., Metge B.J., Liu S., Riker A.I., Samant R.S., Shevde L.A. The hedgehog pathway transcription factor GLI1 promotes malignant behavior of cancer cells by up-regulating osteopontin. J. Biol. Chem. 2009, 284:22888-22897.
35. Das S., Samant R.S., Shevde L.A. Hedgehog signaling induced by breast cancer cells promotes osteoclastogenesis and osteolysis. J. Biol. Chem. 2011, 286:9612-9622.
36. Das S., Tucker J.A., Khullar S., Samant R.S., Shevde L.A. Hedgehog signaling in tumor cells facilitates osteoblast-enhanced osteolytic metastases. PLoS One 2012, 7:e34374.
37. Das S., Samant R.S., Shevde L.A. Nonclassical activation of Hedgehog signaling enhances multidrug resistance and makes cancer cells refractory to Smoothened-targeting Hedgehog inhibition. J. Biol. Chem. 2013, 288:11824-11833.
38. Delany A.M. Matricellular proteins osteopontin and osteonectin/SPARC in pancreatic carcinoma. Cancer Biol. Ther. 2010, 10:65-67.
39. Deng B., Zhang X.F., Zhu X.C., Huang H., Jia H.L., Ye Q.H., Dong Q.Z., Qin L.X. Correlation and prognostic value of osteopontin and Bcl-2 in hepatocellular carcinoma patients after curative resection. Oncol. Rep. 2013, 30:2795-2803.
40. Denhardt D.T., Mistretta D., Chambers A.F., Krishna S., Porter J.F., Raghuram S., Rittling S.R. Transcriptional regulation of osteopontin and the metastatic phenotype: evidence for a Ras-activated enhancer in the human OPN promoter. Clin. Exp. Metastasis 2003, 20:77-84.
41. Desai B., Ma T., Chellaiah M.A. Invadopodia and matrix degradation, a new property of prostate cancer cells during migration and invasion. J. Biol. Chem. 2008, 283:13856-13866.
42. Ding Z., Wu C.J., Chu G.C., Xiao Y., Ho D., Zhang J., Perry S.R., Labrot E.S., Wu X., Lis R., Hoshida Y., Hiller D., Hu B., Jiang S., Zheng H., Stegh A.H., Scott K.L., Signoretti S., Bardeesy N., Wang Y.A., Hill D.E., Golub T.R., Stampfer M.J., Wong W.H., Loda M., Mucci L., Chin L., DePinho R.A. SMAD4-dependent barrier constrains prostate cancer growth and metastatic progression. Nature 2011, 470:269-273.
43. El-Tanani M., Platt-Higgins A., Rudland P.S., Campbell F.C. Ets gene PEA3 cooperates with beta-catenin-Lef-1 and c-Jun in regulation of osteopontin transcription. J. Biol. Chem. 2004, 279:20794-20806.
44. El-Tanani M.K., Campbell F.C., Crowe P., Erwin P., Harkin D.P., Pharoah P., Ponder B., Rudland P.S. BRCA1 suppresses osteopontin-mediated breast cancer. J. Biol. Chem. 2006, 281:26587-26601.
45. El-Tanani M.K., Jin D., Campbell F.C., Johnston P.G. Interferon-induced transmembrane 3 binds osteopontin in vitro: expressed in vivo IFITM3 reduced OPN expression. Oncogene 2010, 29:752-762.
46. Etiz D., Ataizi F.C., Bayman E., Akcay M., Acikalin M.F., Colak E., Ciftci E. Prognostic value of osteopontin in patients treated with primary radiotherapy for head and neck cancer. Asian Pac. J. Cancer Prev. 2013, 14:5175-5178.
47. Fan Y., Zhang X., Yang Z.H., Sun X.W., Li S.N., Zhong L., Cheng X., Wang Y., Ma Y.R. The polymorphisms of osteopontin gene and plasma osteopontin protein levels with susceptibility to colorectal carcinoma. DNA Cell Biol. 2013, 32:594-600.
48. Felten M.K., Khatab K., Knoll L., Schettgen T., Muller-BerndorffH., Kraus T. Changes of mesothelin and osteopontin levels over time in formerly asbestos-exposed power industry workers. Int. Arch. Occup. Environ. Health 2013.
49. Filia A., Elliott F., Wind T., Field S., Davies J., Kukalizch K., Randerson-Moor J., Harland M., Bishop D.T., Banks R.E., Newton-Bishop J.A. Plasma osteopontin concentrations in patients with cutaneous melanoma. Oncol. Rep. 2013, 30:1575-1580.
50. Franzen A., Heinegard D. Isolation and characterization of two sialoproteins present only in bone calcified matrix. Biochem. J. 1985, 232:715-724.
51. Furger K.A., Allan A.L., Wilson S.M., Hota C., Vantyghem S.A., Postenka C.O., Al-Katib W., Chambers A.F., Tuck A.B. Beta(3) integrin expression increases breast carcinoma cell responsiveness to the malignancy-enhancing effects of osteopontin. Mol. Cancer Res. 2003, 1:810-819.
52. Hahnel A., Wichmann H., Kappler M., Kotzsch M., Vordermark D., Taubert H., Bache M. Effects of osteopontin inhibition on radiosensitivity of MDA-MB-231 breast cancer cells. Radiat. Oncol. 2010, 5:82.
53. Han S.S., Lee S.J., Kim W.J., Ryu D.R., Won J.Y., Park S., Cheon M.J. Plasma osteopontin is a useful diagnostic biomarker for advanced non-small cell lung cancer. Tuberc. Respir. Dis. 2013, 75:104-110.
54. Harris L.G., Samant R.S., Shevde L.A. Hedgehog signaling: networking to nurture a promalignant tumor microenvironment. Mol. Cancer Res. 2011, 9:1165-1174.
55. Hartung F., Weber G.F. RNA blood levels of osteopontin splice variants are cancer markers. SpringerPlus 2013, 2:110.
56. He B., Mirza M., Weber G.F. An osteopontin splice variant induces anchorage independence in human breast cancer cells. Oncogene 2006, 25:2192-2202.
57. Hedley B.D., Welch D.R., Allan A.L., Al-Katib W., Dales D.W., Postenka C.O., Casey G., Macdonald I.C., Chambers A.F. Downregulation of osteopontin contributes to metastasis suppression by breast cancer metastasis suppressor 1. Int. J. Cancer 2008, 123:526-534.
58. Hollevoet K., Nackaerts K., Gosselin R., De Wever W., Bosquee L., De Vuyst P., Germonpre P., Kellen E., Legrand C., Kishi Y., Delanghe J.R., van Meerbeeck J.P. Soluble mesothelin, megakaryocyte potentiating factor, and osteopontin as markers of patient response and outcome in mesothelioma. J. Thorac. Oncol. 2011, 6:1930-1937.
59. Hong S.H., Lee H.J., Sohn E.J., Ko H.S., Shim B.S., Ahn K.S., Kim S.H. Anti-nephrolithic potential of resveratrol via inhibition of ROS, MCP-1, hyaluronan and osteopontin in vitro and in vivo. Pharmacol. Rep. 2013, 65:970-979.
60. Hsieh Y.H., Juliana M.M., Hicks P.H., Feng G., Elmets C., Liaw L., Chang P.L. Papilloma development is delayed in osteopontin-null mice: implicating an antiapoptosis role for osteopontin. Cancer Res. 2006, 66:7119-7127.
61. Hsieh Y.H., Margaret Juliana M., Ho K.J., Kuo H.C., van der Heyde H., Elmets C., Chang P.L. Host-derived osteopontin maintains an acute inflammatory response to suppress early progression of extrinsic cancer cells. Int. J. Cancer 2012, 131:322-333.
62. Hsieh I.S., Huang W.H., Liou H.C., Chuang W.J., Yang R.S., Fu W.M. Upregulation of drug transporter expression by osteopontin in prostate cancer cells. Mol. Pharmacol. 2013, 83:968-977.
63. Hsieh Y.H., van der Heyde H., Oh E.S., Guan J.L., Chang P.L. Osteopontin mediates tumorigenic transformation of a preneoplastic murine cell line by suppressing anoikis: an Arg-Gly-Asp-dependent-focal adhesion kinase-caspase-8 axis. Mol. Carcinog. 2013.
64. Huang J., Pan C., Hu H., Zheng S., Ding L. Osteopontin-enhanced hepatic metastasis of colorectal cancer cells. PLoS One 2012, 7:e47901.
65. Imano M., Okuno K., Itoh T., Satou T., Ishimaru E., Yasuda T., Hida J., Imamoto H., Takeyama Y., Shiozaki H. Osteopontin induced by macrophages contribute to metachronous liver metastases in colorectal cancer. Am. Surg. 2011, 77:1515-1520.
66. Incesoy-Ozdemir S., Sahin G., Bozkurt C., Oren A.C., Balkaya E., Ertem U. The relationship between cerebrospinal fluid osteopontin level and central nervous system involvement in childhood acute leukemia. Turk. J. Pediatr. 2013, 55:42-49.
67. Jain S., Chakraborty G., Kundu G.C. The crucial role of cyclooxygenase-2 in osteopontin-induced protein kinase C alpha/c-Src/IkappaB kinase alpha/beta-dependent prostate tumor progression and angiogenesis. Cancer Res. 2006, 66:6638-6648.
68. Kale S., Raja R., Thorat D., Soundararajan G., Patil T.V., Kundu G.C. Osteopontin signaling upregulates cyclooxygenase-2 expression in tumor-associated macrophages leading to enhanced angiogenesis and melanoma growth via alpha9beta1 integrin. Oncogene 2013.
69. Karadag F., Gulen S.T., Karul A.B., Kilicarslan N., Ceylan E., Kuman N.K., Cildag O. Osteopontin as a marker of weight loss in lung cancer. Scand. J. Clin. Lab. Invest. 2011, 71:690-694.
70. Khalil A., Elgedawy J., Faramawi M.F., Elfert A., Salama I., Abbass A., Elsaid H., Elsebaai H. Plasma osteopontin level as a diagnostic marker of hepatocellular carcinoma in patients with radiological evidence of focal hepatic lesions. Tumori 2013, 99:100-107.
71. Khan S.A., Cook A.C., Kappil M., Gunthert U., Chambers A.F., Tuck A.B., Denhardt D.T. Enhanced cell surface CD44 variant (v6, v9) expression by osteopontin in breast cancer epithelial cells facilitates tumor cell migration: novel post-transcriptional, post-translational regulation. Clin. Exp. Metastasis 2005, 22:663-673.
72. Kumar V., Behera R., Lohite K., Karnik S., Kundu G.C. p38 kinase is crucial for osteopontin-induced furin expression that supports cervical cancer progression. Cancer Res. 2010, 70:10381-10391.
73. Kumar S., Patil H.S., Sharma P., Kumar D., Dasari S., Puranik V.G., Thulasiram H.V., Kundu G.C. Andrographolide inhibits osteopontin expression and breast tumor growth through down regulation of PI3 kinase/Akt signaling pathway. Curr. Mol. Med. 2012, 12:952-966.
74. Kurisetty V.V., Johnston P.G., Johnston N., Erwin P., Crowe P., Fernig D.G., Campbell F.C., Anderson I.P., Rudland P.S., El-Tanani M.K. RAN GTPase is an effector of the invasive/metastatic phenotype induced by osteopontin. Oncogene 2008, 27:7139-7149.
75. Kurzbach D., Platzer G., Schwarz T.C., Henen M.A., Konrat R., Hinderberger D. Cooperative unfolding of compact conformations of the intrinsically disordered protein osteopontin. Biochemistry 2013.
76. Laffon A., Garcia-Vicuna R., Humbria A., Postigo A.A., Corbi A.L., de Landazuri M.O., Sanchez-Madrid F. Upregulated expression and function of VLA-4 fibronectin receptors on human activated T cells in rheumatoid arthritis. J. Clin. Invest. 1991, 88:546-552.
77. Lee T.Y., Lin J.T., Wu C.C., Yu C.C., Wu M.S., Lee T.C., Chen H.P., Wu C.Y. Osteopontin promoter polymorphisms are associated with susceptibility to gastric cancer. J. Clin. Gastroenterol. 2013, 47:e55-e59.
78. Li Y., Li L., Wang J.T., Kan X., Lu J.G. Elevated content of osteopontin in plasma and tumor tissues of patients with laryngeal and hypopharyngeal carcinoma associated with metastasis and prognosis. Med. Oncol. 2012, 29:1429-1434.
79. Li N.Y., Weber C.E., Wai P.Y., Cuevas B.D., Zhang J., Kuo P.C., Mi Z. An MAPK-dependent pathway induces epithelial-mesenchymal transition via Twist activation in human breast cancer cell lines. Surgery 2013, 154:404-410.
80. Lim A.M., Rischin D., Fisher R., Cao H., Kwok K., Truong D., McArthur G.A., Young R.J., Giaccia A., Peters L., Le Q.T. Prognostic significance of plasma osteopontin in patients with locoregionally advanced head and neck squamous cell carcinoma treated on TROG 02.02 phase III trial. Clin. Cancer Res. 2012, 18:301-307.
81. Lin F., Cao J., Huang Z., Pei Z., Gu W., Fan S., Li K., Weng J. Effect of thalidomide on the proliferation of hepatoma cells assessed by osteopontin levels in nude mice. Exp. Ther. Med. 2013, 5:1403-1407.
82. Liu W., Xu G., Ma J., Jia W., Li J., Chen K., Wang W., Hao C., Wang Y., Wang X. Osteopontin as a key mediator for vasculogenic mimicry in hepatocellular carcinoma. Tohoku J. Exp. Med. 2011, 224:29-39.
83. Liu J., Xu K., Chase M., Ji Y., Logan J.K., Buchsbaum R.J. Tiam1-regulated osteopontin in senescent fibroblasts contributes to the migration and invasion of associated epithelial cells. J. Cell Sci. 2012, 125:376-386.
84. Lu J.G., Li Y., Li L., Kan X. Overexpression of osteopontin and integrin alphav in laryngeal and hypopharyngeal carcinomas associated with differentiation and metastasis. J. Cancer Res. Clin. Oncol. 2011, 137:1613-1618.
85. Lu D.Y., Yeh W.L., Huang S.M., Tang C.H., Lin H.Y., Chou S.J. Osteopontin increases heme oxygenase-1 expression and subsequently induces cell migration and invasion in glioma cells. Neuro Oncol. 2012, 14:1367-1378.
86. Luo X., Ruhland M.K., Pazolli E., Lind A.C., Stewart S.A. Osteopontin stimulates preneoplastic cellular proliferation through activation of the MAPK pathway. Mol. Cancer Res. 2011, 9:1018-1029.
87. Lv J., Shao Q., Wang H., Shi H., Wang T., Gao W., Song B., Zheng G., Kong B., Qu X. Effects and mechanisms of curcumin and basil polysaccharide on the invasion of SKOV3 cells and dendritic cells. Mol. Med. Rep. 2013, 8:1580-1586.
88. Matsuura M., Suzuki T., Saito T. Osteopontin is a new target molecule for ovarian clear cell carcinoma therapy. Cancer Sci. 2010, 101:1828-1833.
89. Matusan-Ilijas K., Damante G., Fabbro D., Dordevic G., Hadzisejdic I., Grahovac M., Avirovic M., Grahovac B., Jonjic N., Lucin K. EGFR expression is linked to osteopontin and Nf-kappaB signaling in clear cell renal cell carcinoma. Clin. Transl. Oncol. 2013, 15:65-71.
90. McAllister S.S., Gifford A.M., Greiner A.L., Kelleher S.P., Saelzler M.P., Ince T.A., Reinhardt F., Harris L.N., Hylander B.L., Repasky E.A., Weinberg R.A. Systemic endocrine instigation of indolent tumor growth requires osteopontin. Cell 2008, 133:994-1005.
91. Mentor-Marcel R., Lamartiniere C.A., Eltoum I.A., Greenberg N.M., Elgavish A. Dietary genistein improves survival and reduces expression of osteopontin in the prostate of transgenic mice with prostatic adenocarcinoma (TRAMP). J. Nutr. 2005, 135:989-995.
92. Mi Z., Bhattacharya S.D., Kim V.M., Guo H., Talbot L.J., Kuo P.C. Osteopontin promotes CCL5-mesenchymal stromal cell-mediated breast cancer metastasis. Carcinogenesis 2011, 32:477-487.
93. Minai-Tehrani A., Chang S.H., Kwon J.T., Hwang S.K., Kim J.E., Shin J.Y., Yu K.N., Park S.J., Jiang H.L., Kim J.H., Hong S.H., Kang B., Kim D., Chae C.H., Lee K.H., Beck G.R., Cho M.H. Aerosol delivery of lentivirus-mediated O-glycosylation mutant osteopontin suppresses lung tumorigenesis in K-ras (LA1) mice. Cell. Oncol. 2013, 36:15-26.
94. Minai-Tehrani A., Chang S.H., Park S.B., Cho M.H. The O-glycosylation mutant osteopontin alters lung cancer cell growth and migration in vitro and in vivo. Int. J. Mol. Med. 2013, 32:1137-1149.
95. Mirza M., Shaughnessy E., Hurley J.K., Vanpatten K.A., Pestano G.A., He B., Weber G.F. Osteopontin-c is a selective marker of breast cancer. Int. J. Cancer 2008, 122:889-897.
96. Mitra A., Menezes M.E., Pannell L.K., Mulekar M.S., Honkanen R.E., Shevde L.A., Samant R.S. DNAJB6 chaperones PP2A mediated dephosphorylation of GSK3beta to downregulate beta-catenin transcription target, osteopontin. Oncogene 2012, 31:4472-4483.
97. Morrow K.A., Shevde L.A. Merlin: the wizard requires protein stability to function as a tumor suppressor. Biochim. Biophys. Acta 2012, 1826:400-406.
98. Morrow K.A., Das S., Metge B.J., Ye K., Mulekar M.S., Tucker J.A., Samant R.S., Shevde L.A. Loss of tumor suppressor Merlin in advanced breast cancer is due to post-translational regulation. J. Biol. Chem. 2011, 286:40376-40385.
99. Moszynski R., Szubert S., Szpurek D., Michalak S., Sajdak S. Role of osteopontin in differential diagnosis of ovarian tumors. J. Obstet. Gynaecol. Res. 2013, 39:1518-1525.
100. Mu G., Wang H., Cai Z., Ji H. OPN -443C>T genetic polymorphism and tumor OPN expression are associated with the risk and clinical features of papillary thyroid cancer in a Chinese cohort. Cell. Physiol. Biochem. 2013, 32:171-179.
101. Mutrie J.C., Chambers A.F., Tuck A.B. Osteopontin increases breast cancer cell sensitivity to specific signaling pathway inhibitors in preclinical models. Cancer Biol. Ther. 2011, 12:680-690.
102. Pai M.H., Kuo Y.H., Chiang E.P., Tang F.Y. S-Allylcysteine inhibits tumour progression and the epithelial-mesenchymal transition in a mouse xenograft model of oral cancer. Br. J. Nutr. 2012, 108:28-38.
103. Pang H., Cai L., Yang Y., Chen X., Sui G., Zhao C. Knockdown of osteopontin chemosensitizes MDA-MB-231 cells to cyclophosphamide by enhancing apoptosis through activating p38 MAPK pathway. Cancer Biother. Radiopharm. 2011, 26:165-173.
104. Pang H., Lu H., Song H., Meng Q., Zhao Y., Liu N., Lan F., Liu Y., Yan S., Dong X., Cai L. Prognostic values of osteopontin-c, E-cadherin and beta-catenin in breast cancer. Cancer Epidemiol. 2013.
105. Platzer G., Schedlbauer A., Chemelli A., Ozdowy P., Coudevylle N., Auer R., Kontaxis G., Hartl M., Miles A.J., Wallace B.A., Glatter O., Bister K., Konrat R. The metastasis-associated extracellular matrix protein osteopontin forms transient structure in ligand interaction sites. Biochemistry 2011, 50:6113-6124.
106. Poruk K.E., Firpo M.A., Scaife C.L., Adler D.G., Emerson L.L., Boucher K.M., Mulvihill S.J. Serum osteopontin and tissue inhibitor of metalloproteinase 1 as diagnostic and prognostic biomarkers for pancreatic adenocarcinoma. Pancreas 2013, 42:193-197.
107. Raja R., Kale S., Thorat D., Soundararajan G., Lohite K., Mane A., Karnik S., Kundu G.C. Hypoxia-driven osteopontin contributes to breast tumor growth through modulation of HIF1alpha-mediated VEGF-dependent angiogenesis. Oncogene 2013.
108. Ramachandran S., Kwon K.Y., Shin S.J., Kwon S.H., Cha S.D., Lee H.G., Hong Y.B., Bae I., Lee G.H., Cho C.H. Regulatory role of osteopontin in malignant transformation of endometrial cancer. Mol. Biol. Rep. 2013, 40:3623-3629.
109. Ramchandani D., Weber G.F. An osteopontin promoter polymorphism is associated with aggressiveness in breast cancer. Oncol. Rep. 2013, 30:1860-1868.
110. Rangaswami H., Bulbule A., Kundu G.C. Nuclear factor-inducing kinase plays a crucial role in osteopontin-induced MAPK/IkappaBalpha kinase-dependent nuclear factor kappaB-mediated promatrix metalloproteinase-9 activation. J. Biol. Chem. 2004, 279:38921-38935.
111. Rao G., Wang H., Li B., Huang L., Xue D., Wang X., Jin H., Wang J., Zhu Y., Lu Y., Du L., Chen Q. Reciprocal interactions between tumor-associated macrophages and CD44-positive cancer cells via osteopontin/CD44 promote tumorigenicity in colorectal cancer. Clin. Cancer Res. 2013, 19:785-797.
112. Ravindranath A., Yuen H.F., Chan K.K., Grills C., Fennell D.A., Lappin T.R., El-Tanani M. Wnt-beta-catenin-Tcf-4 signalling-modulated invasiveness is dependent on osteopontin expression in breast cancer. Br. J. Cancer 2011, 105:542-551.
113. Rittling S.R. Osteopontin in macrophage function. Expert Rev. Mol. Med. 2011, 13:e15.
114. Robertson B.W., Bonsal L., Chellaiah M.A. Regulation of Erk1/2 activation by osteopontin in PC3 human prostate cancer cells. Mol. Cancer 2010, 9:260.
115. Rud A.K., Boye K., Oijordsbakken M., Lund-Iversen M., Halvorsen A.R., Solberg S.K., Berge G., Helland A., Brustugun O.T., Maelandsmo G.M. Osteopontin is a prognostic biomarker in non-small cell lung cancer. BMC Cancer 2013, 13:540.
116. Samanna V., Wei H., Ego-Osuala D., Chellaiah M.A. Alpha-V-dependent outside-in signaling is required for the regulation of CD44 surface expression, MMP-2 secretion, and cell migration by osteopontin in human melanoma cells. Exp. Cell Res. 2006, 312:2214-2230.
117. Samant R.S., Clark D.W., Fillmore R.A., Cicek M., Metge B.J., Chandramouli K.H., Chambers A.F., Casey G., Welch D.R., Shevde L.A. Breast cancer metastasis suppressor 1 (BRMS1) inhibits osteopontin transcription by abrogating NF-kappaB activation. Mol. Cancer 2007, 6:6.
118. Schultz J., Lorenz P., Ibrahim S.M., Kundt G., Gross G., Kunz M. The functional -443T/C osteopontin promoter polymorphism influences osteopontin gene expression in melanoma cells via binding of c-Myb transcription factor. Mol. Carcinog. 2009, 48:14-23.
119. Schulze E.B., Hedley B.D., Goodale D., Postenka C.O., Al-Katib W., Tuck A.B., Chambers A.F., Allan A.L. The thrombin inhibitor Argatroban reduces breast cancer malignancy and metastasis via osteopontin-dependent and osteopontin-independent mechanisms. Breast Cancer Res. Treat. 2008, 112:243-254.
120. Sfiridaki A., Miyakis S., Pappa C., Tsirakis G., Alegakis A., Kotsis V., Stathopoulos E., Alexandrakis M. Circulating osteopontin: a dual marker of bone destruction and angiogenesis in patients with multiple myeloma. J. Hematol. Oncol. 2011, 4:22.
121. Shang S., Plymoth A., Ge S., Feng Z., Rosen H.R., Sangrajrang S., Hainaut P., Marrero J.A., Beretta L. Identification of osteopontin as a novel marker for early hepatocellular carcinoma. Hepatology 2012, 55:483-490.
122. Sharif S.A., Du X., Myles T., Song J.J., Price E., Lee D.M., Goodman S.B., Nagashima M., Morser J., Robinson W.H., Leung L.L. Thrombin-activatable carboxypeptidase B cleavage of osteopontin regulates neutrophil survival and synoviocyte binding in rheumatoid arthritis. Arthritis Rheum. 2009, 60:2902-2912.
123. Shen H., Weber G.F. The osteopontin-c splice junction is important for anchorage-independent growth. Mol. Carcinog. 2013.
124. Shevde L.A., Samant R.S. Nonclassical hedgehog-gli signaling and its clinical implications. Int. J. Cancer 2013.
125. Shevde L.A., Samant R.S., Paik J.C., Metge B.J., Chambers A.F., Casey G., Frost A.R., Welch D.R. Osteopontin knockdown suppresses tumorigenicity of human metastatic breast carcinoma, MDA-MB-435. Clin. Exp. Metastasis 2006, 23:123-133.
126. Shevde L.A., Metge B.J., Mitra A., Xi Y., Ju J., King J.A., Samant R.S. Spheroid-forming subpopulation of breast cancer cells demonstrates vasculogenic mimicry via hsa-miR-299-5p regulated de novo expression of osteopontin. J. Cell Mol. Med. 2010, 14:1693-1706.
127. Shi Z., Mirza M., Wang B., Kennedy M.A., Weber G.F. Osteopontin-a alters glucose homeostasis in anchorage-independent breast cancer cells. Cancer Lett. 2013.
128. Shinohara M.L., Kim H.J., Kim J.H., Garcia V.A., Cantor H. Alternative translation of osteopontin generates intracellular and secreted isoforms that mediate distinct biological activities in dendritic cells. Proc. Natl. Acad. Sci. U. S. A. 2008, 105:7235-7239.
129. Shojaei F., Scott N., Kang X., Lappin P.B., Fitzgerald A.A., Karlicek S., Simmons B.H., Wu A., Lee J.H., Bergqvist S., Kraynov E. Osteopontin induces growth of metastatic tumors in a preclinical model of non-small lung cancer. J. Exp. Clin. Cancer Res. 2012, 31:26.
130. Singhal H., Bautista D.S., Tonkin K.S., O'Malley F.P., Tuck A.B., Chambers A.F., Harris J.F. Elevated plasma osteopontin in metastatic breast cancer associated with increased tumor burden and decreased survival. Clin. Cancer Res. 1997, 3:605-611.
131. Sodek J., Ganss B., McKee M.D. Osteopontin. Crit. Rev. Oral Biol. Med. 2000, 11:279-303.
132. Stemberger C., Matusan-Ilijas K., Avirovic M., Bulat-Kardum L., Ivancic A., Jonjic N., Lucin K. Osteopontin is associated with decreased apoptosis and alphav integrin expression in lung adenocarcinoma. Acta Histochem. 2013.
133. Sullivan J., Blair L., Alnajar A., Aziz T., Chipitsyna G., Gong Q., Yeo C.J., Arafat H.A. Expression and regulation of nicotine receptor and osteopontin isoforms in human pancreatic ductal adenocarcinoma. Histol. Histopathol. 2011, 26:893-904.
134. Sun Y., Fang S., Dong H., Zhao C., Yang Z., Li P., Wang J. Correlation between osteopontin messenger RNA expression and microcalcification shown on sonography in papillary thyroid carcinoma. J. Ultrasound Med. 2011, 30:765-771.
135. Sun B.S., You J., Li Y., Zhang Z.F., Wang C.L. Osteopontin knockdown suppresses non-small cell lung cancer cell invasion and metastasis. Chin. Med. J. 2013, 126:1683-1688.
136. Sun J., Feng A., Chen S., Zhang Y., Xie Q., Yang M., Shao Q., Liu J., Yang Q., Kong B., Qu X. Osteopontin splice variants expressed by breast tumors regulate monocyte activation via MCP-1 and TGF-beta1. Cell Mol. Immunol. 2013, 10:176-182.
137. Suzuki K., Zhu B., Rittling S.R., Denhardt D.T., Goldberg H.A., McCulloch C.A., Sodek J. Colocalization of intracellular osteopontin with CD44 is associated with migration, cell fusion, and resorption in osteoclasts. J. Bone Miner. Res. 2002, 17:1486-1497.
138. Talbot L.J., Mi Z., Bhattacharya S.D., Kim V., Guo H., Kuo P.C. Pharmacokinetic characterization of an RNA aptamer against osteopontin and demonstration of in vivo efficacy in reversing growth of human breast cancer cells. Surgery 2011, 150:224-230.
139. Tang X., Li J., Yu B., Su L., Yu Y., Yan M., Liu B., Zhu Z. Osteopontin splice variants differentially exert clinicopathological features and biological functions in gastric cancer. Int. J. Biol. Sci. 2013, 9:55-66.
140. Thoms J.W., Dal Pra A., Anborgh P.H., Christensen E., Fleshner N., Menard C., Chadwick K., Milosevic M., Catton C., Pintilie M., Chambers A.F., Bristow R.G. Plasma osteopontin as a biomarker of prostate cancer aggression: relationship to risk category and treatment response. Br. J. Cancer 2012, 107:840-846.
141. Thorsen S.B., Lundberg M., Villablanca A., Christensen S.L., Belling K.C., Nielsen B.S., Knowles M., Gee N., Nielsen H.J., Brunner N., Christensen I.J., Fredriksson S., Stenvang J., Assarsson E. Detection of serological biomarkers by proximity extension assay for detection of colorectal neoplasias in symptomatic individuals. J. Transl. Med. 2013, 11:253.
142. Tilli T.M., Franco V.F., Robbs B.K., Wanderley J.L., da Silva F.R., de Mello K.D., Viola J.P., Weber G.F., Gimba E.R. Osteopontin-c splicing isoform contributes to ovarian cancer progression. Mol. Cancer Res. 2011, 9:280-293.
143. Tilli T.M., Mello K.D., Ferreira L.B., Matos A.R., Accioly M.T., Faria P.A., Bellahcene A., Castronovo V., Gimba E.R. Both osteopontin-c and osteopontin-b splicing isoforms exert pro-tumorigenic roles in prostate cancer cells. Prostate 2012, 72:1688-1699.
144. Tilli T.M., Thuler L.C., Matos A.R., Coutinho-Camillo C.M., Soares F.A., da Silva E.A., Neves A.F., Goulart L.R., Gimba E.R. Expression analysis of osteopontin mRNA splice variants in prostate cancer and benign prostatic hyperplasia. Exp. Mol. Pathol. 2012, 92:13-19.
145. Torres-Martin M., Lassaletta L., San-Roman-Montero J., De Campos J.M., Isla A., Gavilan J., Melendez B., Pinto G.R., Burbano R.R., Castresana J.S., Rey J.A. Microarray analysis of gene expression in vestibular schwannomas reveals SPP1/MET signaling pathway and androgen receptor deregulation. Int. J. Oncol. 2013, 42:848-862.
146. Tuck A.B., O'Malley F.P., Singhal H., Harris J.F., Tonkin K.S., Kerkvliet N., Saad Z., Doig G.S., Chambers A.F. Osteopontin expression in a group of lymph node negative breast cancer patients. Int. J. Cancer 1998, 79:502-508.
147. Tuck A.B., Arsenault D.M., O'Malley F.P., Hota C., Ling M.C., Wilson S.M., Chambers A.F. Osteopontin induces increased invasiveness and plasminogen activator expression of human mammary epithelial cells. Oncogene 1999, 18:4237-4246.
148. Tuck A.B., Elliott B.E., Hota C., Tremblay E., Chambers A.F. Osteopontin-induced, integrin-dependent migration of human mammary epithelial cells involves activation of the hepatocyte growth factor receptor (Met). J. Cell Biochem. 2000, 78:465-475.
149. Tuck A.B., Hota C., Wilson S.M., Chambers A.F. Osteopontin-induced migration of human mammary epithelial cells involves activation of EGF receptor and multiple signal transduction pathways. Oncogene 2003, 22:1198-1205.
150. van den Hoogen C., van der Horst G., Cheung H., Buijs J.T., Pelger R.C., van der Pluijm G. The aldehyde dehydrogenase enzyme 7A1 is functionally involved in prostate cancer bone metastasis. Clin. Exp. Metastasis 2011, 28:615-625.
151. Wang H.H., Wang X.W., Tang C.E. Osteopontin expression in nasopharyngeal carcinoma: its relevance to the clinical stage of the disease. J. Cancer Res. Ther. 2011, 7:138-142.
152. Wang Y., Yan W., Lu X., Qian C., Zhang J., Li P., Shi L., Zhao P., Fu Z., Pu P., Kang C., Jiang T., Liu N., You Y. Overexpression of osteopontin induces angiogenesis of endothelial progenitor cells via the avbeta3/PI3K/AKT/eNOS/NO signaling pathway in glioma cells. Eur. J. Cell Biol. 2011, 90:642-648.
153. Wang X.M., Li J., Yan M.X., Liu L., Jia D.S., Geng Q., Lin H.C., He X.H., Li J.J., Yao M. Integrative analyses identify osteopontin, LAMB3 and ITGB1 as critical pro-metastatic genes for lung cancer. PLoS One 2013, 8:e55714.
154. Weber G.F., Lett G.S., Haubein N.C. Categorical meta-analysis of Osteopontin as a clinical cancer marker. Oncol. Rep. 2011, 25:433-441.
155. Wu J., Pungaliya P., Kraynov E., Bates B. Identification and quantification of osteopontin splice variants in the plasma of lung cancer patients using immunoaffinity capture and targeted mass spectrometry. Biomarkers 2012, 17:125-133.
156. Xiao X., Gang Y., Gu Y., Zhao L., Chu J., Zhou J., Cai X., Zhang H., Xu L., Nie Y., Wu K., Liu Z., Fan D. Osteopontin contributes to TGF-beta1 mediated hepatic stellate cell activation. Dig. Dis. Sci. 2012, 57:2883-2891.
157. Yamaguchi Y., Shao Z., Sharif S., Du X.Y., Myles T., Merchant M., Harsh G., Glantz M., Recht L., Morser J., Leung L.L. Thrombin-cleaved fragments of osteopontin are overexpressed in malignant glial tumors and provide a molecular niche with survival advantage. J. Biol. Chem. 2013, 288:3097-3111.
158. Yang L., Wei L., Zhao W., Wang X., Zheng G., Zheng M., Song X., Zuo W. Down-regulation of osteopontin expression by RNA interference affects cell proliferation and chemotherapy sensitivity of breast cancer MDA-MB-231 cells. Mol. Med. Rep. 2012, 5:373-376.
159. Yuen H.F., Chan K.K., Grills C., Murray J.T., Platt-Higgins A., Eldin O.S., O'Byrne K., Janne P., Fennell D.A., Johnston P.G., Rudland P.S., El-Tanani M. Ran is a potential therapeutic target for cancer cells with molecular changes associated with activation of the PI3K/Akt/mTORC1 and Ras/MEK/ERK pathways. Clin. Cancer Res. 2012, 18:380-391.
160. Zhang G., He B., Weber G.F. Growth factor signaling induces metastasis genes in transformed cells: molecular connection between Akt kinase and osteopontin in breast cancer. Mol. Cell Biol. 2003, 23:6507-6519.
161. Zhang R., Pan X., Huang Z., Weber G.F., Zhang G. Osteopontin enhances the expression and activity of MMP-2 via the SDF-1/CXCR4 axis in hepatocellular carcinoma cell lines. PLoS One 2011, 6:e23831.
162. Zhang Y., Forootan S.S., Kamalian L., Bao Z.Z., Malki M.I., Foster C.S., Ke Y. Suppressing tumourigenicity of prostate cancer cells by inhibiting osteopontin expression. Int. J. Oncol. 2011, 38:1083-1091.
163. Zhao F., Zhang Y., Wang H., Jin M., He S., Shi Y., Guo Y. Blockade of osteopontin reduces alloreactive CD8+ T cell-mediated graft-versus-host disease. Blood 2011, 117:1723-1733.
164. Zhao L., Wang Y., Qu N., Huang C., Chen L. Significance of plasma osteopontin levels in patients with bladder urothelial carcinomas. Mol. Diagn. Ther. 2012, 16:311-316.
165. Zheng J., Hou Z.B., Jiao N.L. Effects of osteopontin downregulation on the growth of prostate cancer PC-3 cells. Mol. Med. Rep. 2011, 4:1225-1231.
166. Zhou C., Zhou H.J., Zhang X.F., Lou L.L., Ye Q.H., Zheng Y., Wang J., Zhu H.T., Dong Q.Z., Jia H.L., Zhu W.W., Guo L., Zhao Y., Gao D.M., Qin L.X. Postoperative serum osteopontin level is a novel monitor for treatment response and tumor recurrence after resection of hepatitis B-related hepatocellular carcinoma. Ann. Surg. Oncol. 2013, 20:929-937.